Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Iovance Biotherapeutics, Inc. (IOVA : NSDQ)

• Company Description    Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells. Number of Employees: 975

• Price / Volume Information    Yesterday's Closing Price: $14.23 Daily Weekly Monthly 20 Day Moving Average: 17,840,084 shares Shares Outstanding: 452.97 (millions) Market Capitalization: $6,445.78 (millions) Beta: 0.76 52 Week High: $15.30 52 Week Low: $1.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 63.56% 65.30% 12 Week 225.63% 220.41% Year To Date 421.24% 365.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 825 INDUSTRIAL ROAD SUITE 100 - SAN CARLOS,CA 94070 USA ph: 650-260-7120 fax: - ir@iovance.com http://www.iovance.com

• General Corporate Information    Officers Frederick G. Vogt - Interim Chief Executive Officer;President and Gene Corleen Roche - Chief Financial Officer Michael Weiser - Director Ryan D. Maynard - Director Iain Dukes - Director Peer Information Iovance Biotherapeutics, Inc. (CORR.) Iovance Biotherapeutics, Inc. (RSPI) Iovance Biotherapeutics, Inc. (CGXP) Iovance Biotherapeutics, Inc. (BGEN) Iovance Biotherapeutics, Inc. (GTBP) Iovance Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 462260100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 452.97 Most Recent Split Date: 9.00 (0.01:1) Beta: 0.76 Market Capitalization: $6,445.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.76 Price/Cash Flow: - Price / Sales: 19.84 EPS Growth vs. Year Ago Period: 66.67% vs. Previous Quarter: 42.11% Sales Growth vs. Year Ago Period: 65.65% vs. Previous Quarter: 39.04% ROE 09/30/26 - - 06/30/26 - -40.51 03/31/26 - -50.17 ROA 09/30/26 - - 06/30/26 - -31.65 03/31/26 - -38.77 Current Ratio 09/30/26 - - 06/30/26 - 4.34 03/31/26 - 3.60 Quick Ratio 09/30/26 - - 06/30/26 - 3.82 03/31/26 - 3.15 Operating Margin 09/30/26 - - 06/30/26 - -89.11 03/31/26 - -123.92 Net Margin 09/30/26 - - 06/30/26 - -89.11 03/31/26 - -123.92 Pre-Tax Margin 09/30/26 - - 06/30/26 - -90.42 03/31/26 - -124.24 Book Value 09/30/26 - - 06/30/26 - 1.62 03/31/26 - 1.62 Inventory Turnover 09/30/26 - - 06/30/26 - 3.09 03/31/26 - 3.27 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©